Search
semagacestat
Indications:
- developed to treat Alzheimer's disease
- development halted in phase 3 trials
Adverse effects:
- may worsen cognition in Alzheimer's patients
- increased risk of skin cancer
Mechanism of action:
- inhibits APP gamma-secretase
General
neurologic agent
amide
enzyme inhibitor
Database Correlations
PUBCHEM cid=9843750
References
- MSNBC, Reuters, 8/17/2010
http://www.msnbc.msn.com/id/38737158/ns/health-alzheimers_disease
- Doody RS et al.
A Phase 3 trial of semagacestat for treatment of Alzheimer's
disease.
N Engl J Med 2013 Jul 25; 369:341
PMID: 23883379